Showing results (711-720 of 746) with videos related to
Sort By:
Pageof 75
Lancet (London, England)|April 20, 2020
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trialJeff P Sharman, Miklos Egyed, Wojciech Jurczak, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2025
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaJennifer A Woyach, Lugui Qiu, Sebastian Grosicki, et al.Leukemia|November 26, 2022
Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's MacroglobulinemiaIrene Dogliotti, Cristina Jiménez, Marzia Varettoni, et al.Anticancer Research|July 5, 2020
Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational StudyBartosz Pula, Elzbieta Iskierka-Jazdzewska, Monika Dlugosz-Danecka, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|October 1, 2025
Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G CommitteeGandhi Damaj, Adèle de Masson, Peter Dreger, et al.Bone Marrow Transplantation|October 1, 2025
Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G CommitteeGandhi Damaj, Adèle de Masson, Peter Dreger, et al.The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|January 27, 2016
17α-Estradiol Alleviates Age-related Metabolic and Inflammatory Dysfunction in Male Mice Without Inducing FeminizationMichael B Stout, Frederik J Steyn, Michael J Jurczak, et al.Blood|October 7, 2025
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemiaJennifer R Brown, Bastien Nguyen, Sai Prasad Desikan, et al.Lancet (London, England)|July 9, 2026
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trialMatthew S Davids, Toby A Eyre, Jennifer A Woyach, et al.Cell Metabolism|August 2, 2011
Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in miceAndreas L Birkenfeld, Hui-Young Lee, Fitsum Guebre-Egziabher, et al.Pageof 75